Shares of Kadmon Holdings Inc. (KDMN) rose 19% in extended trading on Monday, following positive top line results from the Company's phase II study of KD025 in Idiopathic Pulmonary Fibrosis. When we alerted our premium subscribers to Kadmon Holdings on January 8, 2018, the stock was trading around $3.70.
from RTT - Biotech http://ift.tt/2EnYgO8
via IFTTT
No comments:
Post a Comment